ORIC

News ORIC Pharmaceuticals Stock Nosedives 25% After Hours: What Is Going On?

14d ago

News ORIC Pharmaceuticals GAAP EPS of -$0.34 misses by $0.02

28d ago

SEC filing ORIC Reports $420M Cash, $19M Net Income, +12% YoY, Rinzimetostat RP3D Selected for Himalayas-1 Phase 3 mCRPC Trial

28d ago

Insider trade Sale by Dominic Piscitelli (Chief Financial Officer)

95d ago

News Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff

139d ago

News ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor

153d ago

Scanner Unusual volume (z=6.7)

160d ago

Scanner Unusual volume (z=6.2)

162d ago

Scanner Unusual volume (z=6.2)

163d ago

Scanner Unusual volume (z=6.2)

164d ago